PDF(Pubmed)
Abstract：
In 1982, the Food and Drug Administration (FDA) of the United States of America approved isotretinoin (13-cis-retinoic acid), a retinoid derivative of vitamin A, to treat severe recalcitrant acne vulgaris. Apart from its prescribed use for severe acne, evidence suggests that isotretinoin is commonly used off-label to treat mild-to-moderate acne, inflammatory skin conditions, genodermatoses, skin cancer, and other skin disorders. This is due to its anti-inflammatory, immunomodulatory, and antineoplastic properties. Some \"off-label\" use is successful, while others are ineffective. Therefore, this information is essential to clinicians for deciding on the appropriate use of isotretinoin. In this article, we aim to review the most updated evidence-based data about the use of oral isotretinoin in dermatology.
摘要：
1982年，美国食品和药物管理局（FDA）批准异维A酸（13-顺式-视黄酸），维生素A的类维生素A衍生物，治疗严重顽固性寻常痤疮。除了用于严重痤疮的处方外，证据表明，异维A酸通常用于治疗轻度至中度痤疮，炎性皮肤状况，遗传性皮肤病，皮肤癌,和其他皮肤病。这是由于它的抗炎作用,免疫调节,和抗肿瘤特性。某些“标签外”使用成功，而其他人是无效的。因此,这些信息对于临床医生决定异维甲酸的适当使用至关重要.在这篇文章中,我们的目的是回顾最新的关于在皮肤科使用口服异维甲酸的循证数据.
